Early impact of maternal RSV vaccination on bronchiolitis hospitalisation and critical care admissions in infants under age 3 months, England, September 2024 to March 2026
- Journal
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (Q1)
- Published
- 1 September 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Jonathan Broad, Matthew Wilson, Jaime Borjas-Howard, Merryn Voysey, Simon B Drysdale, Nick Andrews, et al.
- PMID
- 42725370
- DOI
- 10.2807/1560-7917.ES.2026.31.36.2600752
Why clinicians should know about it
- Picked for Pediatrics and Child Health (paper of the day, 16 September 2026): Maternal RSV vaccine reduces bronchiolitis hospitalisations
Abstract
We conducted a time series analysis of hospitalisation and critical care admissions to evaluate the impact of maternal respiratory syncytial virus (RSV) vaccination in England from September 2024 to March 2026 in infants < 3 months of age. All bronchiolitis admissions decreased by 39.3% (IRR: 0.607, 95% CI: 0.576-0.640), and RSV bronchiolitis admissions by 62.6% (IRR: 0.374, 95% CI: 0.344-0.407). We estimated a 41.0% reduction in bronchiolitis critical care admissions (IRR: 0.590, 95% CI: 0.531-0.657). Maternal vaccine coverage was 55.1%. These findings support efforts to expand vaccine uptake.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.